Unknown

Dataset Information

0

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.

ABSTRACT: Missing Electronic Supplementary Materials.

SUBMITTER: van Helden EJ 

PROVIDER: S-EPMC7645532 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.

van Helden E J EJ   Elias S G SG   Gerritse S L SL   van Es S C SC   Boon E E   Huisman M C MC   van Grieken N C T NCT   Dekker H H   van Dongen G A M S GAMS   Vugts D J DJ   Boellaard R R   van Herpen C M L CML   de Vries E G E EGE   Oyen W J G WJG   Brouwers A H AH   Verheul H M W HMW   Hoekstra O S OS   der Houven van Oordt C W Menke-van CWM  

European journal of nuclear medicine and molecular imaging 20200901 10

Missing Electronic Supplementary Materials. ...[more]

Similar Datasets

Unknown 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer.
| S-EPMC4745807 | biostudies-literature
Unknown [89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.
| S-EPMC9890134 | biostudies-literature
Unknown Evaluation of PET/CT imaging with [89Zr]Zr-DFO-girentuximab: a phase 1 clinical study in Japanese patients with renal cell carcinoma (Zirdac-JP).
| S-EPMC11322881 | biostudies-literature
Unknown RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
| S-EPMC6822250 | biostudies-literature
Unknown Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer.
| S-EPMC5955803 | biostudies-literature
Unknown FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
| S-EPMC5348362 | biostudies-literature
Unknown 89Zr-girentuximab PET/CT Enables Noninvasive Assessment of Indeterminate Renal Masses and Metastatic Clear-Cell Renal Cell Carcinoma
| S-EPMC12944229 | biostudies-literature
Unknown Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
| S-EPMC10507485 | biostudies-literature
Unknown Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging.
| S-EPMC3538910 | biostudies-literature
Unknown Toward Optimized <sup>89</sup>Zr-Immuno-PET: Side-by-Side Comparison of [<sup>89</sup>Zr]Zr-DFO-, [<sup>89</sup>Zr]Zr-3,4,3-(LI-1,2-HOPO)- and [<sup>89</sup>Zr]Zr-DFO*-Cetuximab for Tumor Imaging: Which Chelator Is the Most Suitable?
| S-EPMC9611803 | biostudies-literature